Presented by Spiros P Hiotis, MD SS21 Videos Solid Organ and Foregut: V047

Peritoneal cancer is a rare and aggressive cancer. It is sometimes called the "silent killer" because it usually does not cause symptoms until it is in advanced stages. But there is hope. It is possible to treat.
Although it is rare, it is sometimes seen as early as 25 years old.
Symptoms include pain in the abdomen, pelvic area, and back.
If you experience any of these symptoms, see your doctor as soon as possible. September is Peritoneal Cancer Awareness Month. If you have any questions or concerns about this video, please comment below.

John L. Marshall, MD; Cathy Eng, MD, FACP; Michael A. Morse, MD; Johanna C. Bendell, MD; and Dale R. Shepard, MD, PhD, FACP, highlight liver-directed treatment options and considerations for hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer who relapse.

Cassidy Doucette, DNP, APRN, teaches about the role of palliative care, and appropriate conversations with patients and families, during the treatment of peritoneal carcinomatosis.

Ms. Mayurakshy Sanyal, from Bangladesh shares her thoughts about the treatment, care and support given to her aunt for #PeritonealCarcinoma.
She also thanks Dr. Ajit Pai, Senior Consultant & Lead - GI Surgical Oncology, the other clinical teams and International Patient services team for their valuable support & guidance.

#Apollo #PatientTestimonial #CancerCare #BestFacilities #ApolloProton #Chennai

Colorectal peritoneal metastases or CPM means a bowel cancer has spread (or metastasised) within the abdomen onto the peritoneum.

The peritoneum is the lining covering the surface of abdominal organs and the abdominal wall. In CPM, cells from the bowel cancer have broken free and spread onto surface of the peritoneum and other organs. In terms of colorectal cancer staging, CPM is stage 4.


o Between 5-10% of patients with a bowel cancer will already have peritoneal metastases and this is usually identified at the time of initial surgery. This is referred to as “synchronous colorectal peritoneal metastases”.

o Approximately 20-50% of patients develop CPM in the follow-up period after bowel cancer surgery. This is also referred to as “peritoneal recurrence” or “metachronous colorectal peritoneal metastases”.

Mr Umar Shariff is Consultant General and Colorectal Surgeon at Good Hope Hospital, University Hospitals Birmingham NHS Foundation Trust, and BMI The Priory and Edgbaston Hospitals.

Name: High Five to HIPEC: Finding hope and health with peritoneal cancer
Date: June 25, 2022 (Saturday)
Time: 9am to noon PDT
Format: Virtual
Chairs: Harveshp D. Mogal, MD, MS and Stacey A. Cohen, MD
Agenda: Listed below


- Introductions - Harveshp D. Mogal, MD, MS, Stacey A. Cohen, MD, Meredith Fane, MPA

- Role of HIPEC in Peritoneal Cancers (general overview) - Harveshp D. Mogal, MD, MS

- Role of Systemic Treatment in Patients with Peritoneal Cancers - Stacey A. Cohen, MD

- HIPEC in Ovarian Cancer (GYN ONC) - Barbara A. Goff, MD

Break

- UWMC/FHCC HIPEC program overview - Harveshp D. Mogal, MD, MS

- Panel discussion - Tal Ozery, MS, RD (Nutritionist), Barbara A. Goff, MD (Gynecology Oncologist), Jenica Holt, PT, DPT, CLT (Physical Therapist), Allyssa Dwyer, BSN, RN-BC, OCN (Clinical Nurse Coordinator), Harveshp D. Mogal, MD, MS (Surgical Oncologist), Stacey A. Cohen, MD (Medical Oncologist)

- Patient stories

- Remarks from ACPMP Research Foundation - James Carroll (President)

- Remarks from PMP Pals - Adele Jasion (Vice President)

Q&A

- Closing remarks - Harveshp D. Mogal, MD, MS